Navigation Links
AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimer's Disease Research
Date:7/12/2012

ted a new, flexible approach to neuroscience that would allow us to tap into the most exciting science and discoveries that exist in labs around the world. The A5 alliance, under the leadership of Dr. Paul, is a prime example of the great minds we hope to bring together in the search for new medicines to help people who suffer from neurodegenerative diseases, psychiatric disorders and pain."

Under the terms of the A5 alliance, AstraZeneca will fund the academic research and members of AstraZeneca's Neuroscience Innovative Medicines unit will contribute programme management and scientific expertise. The academic alliance members will contribute their disease area knowledge and expertise, as well as lead specific aspects of the research programme in their laboratories.

Notes to Editors:

About Alzheimer's disease

Alzheimer's disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually even the ability to carry out the simplest tasks of daily living. In most people with Alzheimer's, symptoms first appear after age 60, and Alzheimer's disease is the most common cause of dementia among older people. The National Institutions of Health National Institute on Aging suggests that as many as 5.1 million Americans have Alzheimer's disease.

About AstraZeneca

AstraZeneca (NYSE: AZN) is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

About The Feinstein Insti
'/>"/>

SOURCE AstraZeneca
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Acquires Neuroscience Assets From Link Medicine
2. Genpact and AstraZeneca Win Outsourcing Center and SSON Awards
3. AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
4. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
5. Court Preliminarily Deems Millennium Laboratories Press Release Misleading
6. FMC Corporation Acquires Phytone, Ltd., a Leading European Natural Colors Business
7. Denton Vacuum Ships Breakthrough Wafer-level Optics Development System to Leading German R&D Organization
8. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
9. Software Pioneer Leaves $10 Million Bequest To Five Leading Non-profits In Health And Drug Policy Reform
10. PeaceHealth Laboratories New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse
11. Remedy Informatics Named "Cool Vendor" in Life Sciences by Leading Technology Analyst Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... San Fernando Valley, CA (PRWEB) , ... June 29, 2015 , ... ... offering non-invasive treatments designed to lift and tighten sagging skin. Ulthera is a special ... or surgery. Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is ...
(Date:6/29/2015)... New York, NY (PRWEB) , ... June 29, ... ... health dietary supplement with Citicoline (Cognizin®) from Kyowa Hakko Bio to French consumers. ... protect the macular cells from oxidative stress caused by free radicals. In addition ...
(Date:6/29/2015)... Eagan, Minnesota (PRWEB) , ... June 29, 2015 ... ... Cross) today announced the promotion of two leaders with the Commercial Markets division, ... individuals, small and large employers, and Minnesota-headquartered companies with regional, national and international ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... and pharmacist guided, safe, informed, responsible and legal access to Health Canada's medical ... West. , NAC provides education on how Health Canada's medical marijuana system works. ...
(Date:6/29/2015)... ... 29, 2015 , ... Visiting retirement communities and interviewing at-home caregivers has just ... search for senior care on http://www.SeniorsGuideOnline.com . , The helpful “cheat” sheets, like ... assisted living , rehab, and nursing home communities . , “’What to Ask ...
Breaking Medicine News(10 mins):Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 2Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 3Health News:New Checklists and Question Sheets for Visiting Retirement Communities, Interviewing Home Health Caregivers Available From Seniors Guide 2Health News:New Checklists and Question Sheets for Visiting Retirement Communities, Interviewing Home Health Caregivers Available From Seniors Guide 3
... new study, researchers from the Cornell University in the ... Study //of Youth in 1979, to analyze the correlation ... causes of death – smoking and obesity. Their ... forthcoming July issue of the Journal of Labor Economics, ...
... older adults Age-related Macular Degeneration (AMD) is one of the ... to develop the disease may partly depend upon his diet.// ... concern rather than the quantity, according to a ... for Nutrition and Vision Research , at Tufts University. ...
... effective agent for treating metastatic renal cell cancer, a disease ... ,There is an urgent need for more active ... point of origin to another part of the body) renal ... is estimated to be less than 10 percent, according to ...
... breast cancer, due to an inherited gene but she wasn't prepared ... in Britain to have a preventative double mastectomy and has is ... presenter was 11 years old when her mother, Wendy Watson, become ... double mastectomy to prevent her from developing the condition that killed ...
... by government are needed to improve mental health in Australia//. ... is in need of a new nationalwise approach with acute-care ... report on the Time for Service says mental health funding ... 5 years was being made. ,It added, about ...
... study by scientists at the Lawrence Livermore Berkeley National Library revealed ... //as they age, and the effects of dwarfism begins to take ... collected two years ago, over a four-month period, .from 97 healthy ... called flow cytometry was employed to ‘sort’ out the sperms for ...
Cached Medicine News:Health News:Quality Of Dietary Carbohydrates May Determine Quality Of Eye Sight 2Health News:Quality Of Dietary Carbohydrates May Determine Quality Of Eye Sight 3Health News:Sunitinib a Promising Agent for Treatment of Renal Cell Cancer 2Health News:A 24 Year Old Girls Undergoes Double Mastectomy To Prevent Breast Cancer 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: